TY - JOUR
T1 - Stereotactic Body Radiation Therapy for Primary Renal Cell Carcinoma
T2 - A Case-Based Radiosurgery Society Practice Guide
AU - Barbour, Andrew B.
AU - Upadhyay, Rituraj
AU - Anderson, August C.
AU - Kutuk, Tugce
AU - Kumar, Ritesh
AU - Wang, Shang Jui
AU - Psutka, Sarah P.
AU - Fekrmandi, Fatemeh
AU - Skalina, Karin A.
AU - Bruynzeel, Anna M.E.
AU - Correa, Rohann J.M.
AU - Dal Pra, Alan
AU - Biancia, Cesar Della
AU - Hannan, Raquibul
AU - Louie, Alexander
AU - Singh, Anurag K.
AU - Swaminath, Anand
AU - Tang, Chad
AU - Teh, Bin S.
AU - Zaorsky, Nicholas G.
AU - Lo, Simon S.
AU - Siva, Shankar
N1 - Publisher Copyright:
© 2024 American Society for Radiation Oncology
PY - 2025/1
Y1 - 2025/1
N2 - Traditionally, renal cell carcinoma (RCC) was considered a radioresistant tumor, thereby limiting definitive radiation therapy management options. However, several recent studies have demonstrated that stereotactic body radiation therapy (SBRT) can achieve high rates of local control for the treatment of primary RCC. In the setting of expanding use of SBRT for primary RCC, it is crucial to provide guidance on practical considerations such as patient selection, fractionation, target delineation, and response assessment. This is particularly important in challenging scenarios where a paucity of evidence exists, such as in patients with a solitary kidney, bulky tumors, or tumor thrombus. The Radiosurgery Society endorses this case-based guide to provide a practical framework for delivering SBRT to primary RCC, exemplified by 3 cases. This article explores topics of tumor size and dose fractionation, impact on renal function and treatment in the setting of a solitary kidney, and radiation's role in the management of inferior vena cava tumor thrombus. Additionally, we review existing evidence and expert opinion on target delineation, advanced techniques such as magnetic resonance imaging guided SBRT, and SBRT response assessment.
AB - Traditionally, renal cell carcinoma (RCC) was considered a radioresistant tumor, thereby limiting definitive radiation therapy management options. However, several recent studies have demonstrated that stereotactic body radiation therapy (SBRT) can achieve high rates of local control for the treatment of primary RCC. In the setting of expanding use of SBRT for primary RCC, it is crucial to provide guidance on practical considerations such as patient selection, fractionation, target delineation, and response assessment. This is particularly important in challenging scenarios where a paucity of evidence exists, such as in patients with a solitary kidney, bulky tumors, or tumor thrombus. The Radiosurgery Society endorses this case-based guide to provide a practical framework for delivering SBRT to primary RCC, exemplified by 3 cases. This article explores topics of tumor size and dose fractionation, impact on renal function and treatment in the setting of a solitary kidney, and radiation's role in the management of inferior vena cava tumor thrombus. Additionally, we review existing evidence and expert opinion on target delineation, advanced techniques such as magnetic resonance imaging guided SBRT, and SBRT response assessment.
UR - https://www.scopus.com/pages/publications/85199940758
U2 - 10.1016/j.prro.2024.06.012
DO - 10.1016/j.prro.2024.06.012
M3 - Article
C2 - 39019209
AN - SCOPUS:85199940758
SN - 1879-8500
VL - 15
SP - 74
EP - 85
JO - Practical Radiation Oncology
JF - Practical Radiation Oncology
IS - 1
ER -